跳至主要内容
临床试验/NCT05688644
NCT05688644Enrolling By Invitation不适用

Efficacy and Safety of Sacral Neuromodulation With InterStim II in Neurogenic Bladder and/or Bowel Patients

Omri Schwarztuch Gildor1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2021年12月19日最近更新:
适应症

试验速览

阶段
不适用
状态
Enrolling By Invitation
发起方
入组人数
100
试验地点
1
主要终点
Decrease of at least 50% in number of catheterizations per day

研究概览

简要总结

The goal of this observational study is to evaluate efficacy and safety of sacral neuromodulation in neurogenic patients compared to non-neurogenic (idiopathic) patients. [. The main question[s] it aims to answer are:

  • determine efficacy and safety of the therapy in neurogenic patients.
  • compare outcomes of the therapy to idiopathic patients.

If there is a comparison group: Researchers will compare the outcomes of the therapy between the neurogenic and non-neurogenic subset of patients.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who underwent InterStim II advanced evaluation for approved indication

排除标准

  • 未提供

结局指标

主要结局

Decrease of at least 50% in number of catheterizations per day

时间窗: 1 year

Decrease of at least 50% in number of fecal incontinence episodes

时间窗: 1 year

Decrease of at least 50% in number of urge urinary incontinence episodes

时间窗: 1 year

次要结局

  • Number of revision surgeries(1 year)
  • number of follow-up visits for programming and/or troubleshooting(1 year)

研究者

发起方
Omri Schwarztuch Gildor
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Omri Schwarztuch Gildor

Urologist

Clalit Health Services

研究点 (1)

Loading locations...

相似试验

Sacral Neuromodulation in Neurogenic Patients | 临床试验